Activity profile of the novel aziridinylbenzoquinones MeDZQ and RH1 in human tumour xenografts

Jeffrey Cummings, Alison Ritchie, John Butler, Timothy H Ward, Simon Langdon

Research output: Contribution to journalArticlepeer-review

Abstract

RH1 and MeDZQ represent novel aziridinylbenzoquinones that can be activated by DT-diaphorase to form unique DNA lesions. RH1 is due to enter a phase 1 clinical trial in the United Kingdom in the summer of 2003, where pharmacodynamic monitoring of DT-diaphorase will be performed.
Original languageEnglish
Pages (from-to)3979-83
Number of pages5
JournalAnticancer research
Volume23
Issue number5A
Publication statusPublished - 2003

Keywords / Materials (for Non-textual outputs)

  • Animals
  • Antineoplastic Agents
  • Aziridines
  • Benzoquinones
  • Carcinoma, Non-Small-Cell Lung
  • Colonic Neoplasms
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Lung Neoplasms
  • Mice
  • Mice, Nude
  • NAD(P)H Dehydrogenase (Quinone)
  • Transplantation, Heterologous
  • Xenograft Model Antitumor Assays

Fingerprint

Dive into the research topics of 'Activity profile of the novel aziridinylbenzoquinones MeDZQ and RH1 in human tumour xenografts'. Together they form a unique fingerprint.

Cite this